Anti-CTLA-4 or anti-PD-L1/PD-1 fully humanized antibodies, which target immune checkpoint molecules expressed by cTreg cells upon activation, have shown promising results in clinical studies treating various cancer types (31, 33). This evidence concerns the gene PDCD1 and cancer.